Veracyte (VCYT) Cash & Equivalents (2012 - 2026)

Veracyte has disclosed Cash & Equivalents across 15 years of filings, most recently posting $263.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $263.1 million, up 41.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $263.1 million (up 41.38% YoY), and the FY2025 annual result was $362.6 million, up 51.65% from the prior year.
• Cash & Equivalents came in at $263.1 million for Q1 2026 at Veracyte, down from $362.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $362.6 million in Q4 2025 to a low of $153.4 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $209.2 million (2024), against an average of $219.7 million.
• Across the five-year window, Cash & Equivalents tumbled 53.15% in 2022 and soared 51.65% in 2025, its largest moves.
• Veracyte's Cash & Equivalents stood at $154.2 million in 2022, then soared by 40.33% to $216.5 million in 2023, then grew by 10.46% to $239.1 million in 2024, then soared by 51.65% to $362.6 million in 2025, then declined by 27.43% to $263.1 million in 2026.
• The last three Cash & Equivalents figures came in at $263.1 million (Q1 2026), $362.6 million (Q4 2025), and $315.6 million (Q3 2025), per Business Quant data.